Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > Voting Down The Midatech Deal
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(370)
•••
Comment by OttawaPeteron Jan 25, 2023 11:42am
120 Views
Post# 35245298

RE:RE:RE:Voting Down The Midatech Deal

RE:RE:RE:Voting Down The Midatech Deal

fuzzyjr wrote: keep tooting your horn Pete - that's all u got. Any back up plans discussed here are pathetic at best. Keep screaming n honking tho allowing all to see your full ignorance on display.
no clue at all & pee poor rebuttal to anything relevant. Lots of noise , whining &  sneviling - no plan to move forward & not applying enough pressure to pop a pimple let alone try and bring people together with anytime of solid plan.

 

again, you're unhinged, overtly angry & a sniveling troll--- you're the only one screaming. 

Not my obligation to provide what I think is best way to attempt to move forward & wont on this forum. That said, you've no idea what I'm doing off this board so prolly shouldn't comment on things you know nothing about--- I know, I know, it is only thing you know how & can do with your pathetic, angry life--- Doesn't mean we have to listen to it. 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities